Invest in a
healthier tomorrow

Our real-world veterinary disease models predict human responses more accurately than laboratory animal models. Data from veterinary clinical studies provide valuable insights into the safety and efficacy of our drug candidates, as well as treatment regimen. This data informs our human clinical trial protocols. Additionally, this research has the potential to develop important veterinary medical solutions, such as our anticancer veterinary pharmaceutical STELFONTA^®.

Our oncology programme is investigating the potential for our lead candidate tigilanol tiglate to treat a range of solid tumours. Two monotherapy trials are underway in soft tissue sarcoma (Phase II pilot) and head and neck cancer (Phase II). Tigilanol tiglate has been awarded Orphan Drug Designation by the FDA for the treatment of soft tissue sarcoma.

Our wound healing drug candidate, EBC-1013, has the potential to revolutionise the way chronic and acute wounds and burns are treated in the clinic. A first-in-human Phase I safety trial for EBC-1013, recruiting patients with venous leg ulcers, will shortly commence.

Antibiotics is a new area of interest for QBiotics, with considerable potential. Our approach is to disarm bacteria (via virulence disruption) rather than kill them outright, thus producing less evolutionary pressure for development of bacterial resistance. We believe our programme could provide solutions to the continued rise of multiple resistant organisms.

We derive an advantage by applying phenotypic screening to small molecules identified through our EcoLogic™ discovery platform enabling:

• Identification at an early stage in development to determine whether they produce desirable effects related to the disease or disease-associated cellular processes. It is likely that the results from in vivo studies will translate into clinical potential, irrespective of how they work.
• Greater potential to uncover activity against previously unidentified targets, or activity that simultaneously affects more than one target

Tigilanol tiglate, marketed as STELFONTA^®*, has been commercially available as a pharmaceutical for the treatment of canine mast cell tumours since 2020.

STELFONTA^® has been approved by the United States Food & Drug Administration - Center for Veterinary Medicine (FDA-CVM), European Medicines Agency (EMA), Switzerland's Swissmedic, the Veterinary Medicines Directorate (VMD) in the United Kingdom and the Australian Pesticides and Veterinary Medicines Authority (APVMA).

*This link will take you to a product site that contains information that may not comply with the Australian regulatory requirements